Skip to content
AnalystLens
Back to MRNABalance Sheet

Moderna, Inc. Deferred Revenue 2017-2026 | MRNA

Annual FY2017–FY2025 · quarterly through Q1 FY2026

Latest annual · FY2025

$99.0M

−35.3%YoY vs FY2024Source: 10-KFY2025

From $96.7M in FY2017 to $99.0M in FY2025: 1.0× in 8 years.

By quarter▲▼ vs a year before
Fiscal yearQ1Q2Q3Q4
FY26$102M−18.4%Not reportedNot reportedNot reported
FY25$125M−77.6%$218M−68.9%$163M−57.0%$99M−35.3%
FY24$559M−54.1%$702M−32.5%$379M−72.4%$153M−73.1%
FY23$1.2B−78.2%$1.0B−74.6%$1.4B−65.7%$568M−72.1%
FY22$5.6B−25.7%$4.1B−43.9%$4.0B−49.8%$2.0B−67.4%

Shaded by size: darkest is the largest quarter shown; ringed is the latest reported; a dash marks a quarter with no separate figure. Each quarter sits by its period-end date.

Key Statistics

Trend DirectionDeclining
CAGR

−52.0%

FY2020
$3.87B
FY2025
$99.0M

5 years selected · on the chart

01—History

Deferred Revenue History

Year-over-year comparison from 10-K annual reports

  9. $99.0M
YoY changeLargest recent move−73.1%in FY24Latest −35.3%

1 older move runs past ±150% (largest +6008.0%); point at, tap or drag across the bars to read one.

02—Ledger

Deferred Revenue, period by period

PeriodValueChangeSource
FY2025$99.0M−35.3%10-K
FY2024$153.0M−73.1%10-K
FY2023$568.0M−72.1%10-K
FY2022$2.04B−67.4%10-K
FY2021$6.25B+61.7%10-K
FY2020$3.87B+6008.0%10-K
FY2019$63.3M−41.9%10-K
FY2018$109.1M+12.7%10-K
FY2017$96.7M—10-K

03—Questions

What is deferred revenue?

Deferred revenue represents payments received in advance for goods or services that have not yet been delivered to customers.

What is Moderna, Inc.'s current deferred revenue?

Moderna, Inc. (MRNA) annual deferred revenue for 2025 was $99.0M, a 35.29% decline from 2024. Moderna, Inc. deferred revenue for the quarter ending March 31, 2026 was $102.0M.

What was Moderna, Inc.'s deferred revenue in 2024?

Moderna, Inc. annual deferred revenue for 2024 was $153.0M, a 73.06% decline from 2023.

What was Moderna, Inc.'s deferred revenue in 2023?

Moderna, Inc. annual deferred revenue for 2023 was $568.0M, a 72.13% decline from 2022.

What is Moderna, Inc.'s 5-year deferred revenue CAGR?

Moderna, Inc. deferred revenue grew at a compound annual growth rate (CAGR) of 51.95% from FY2020 to FY2025, going from $3.87B to $99.0M over 5 years.

Company
Moderna, Inc.
Ticker
MRNA
Sector
Healthcare
Industry
Biological Products, (No Diagnostic Substances)
View company profile →